Scientific Publications
2023
Perdiguero et al. Potency and durability of T and B cell immune responses after homologous and heterologous vector delivery of a trimer-stabilized, membrane-displayed HIV-1 clade ConC Env protein. Frontiers in Immunology. Nov 2023
Lelièvre et al. CD40.HIVRI.ENV Vaccine induces strong and durable immune responses: ANRS/VRI06 Trial. CROI. Feb 2023
Perdiguero et al. Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study. Frontiers in Immunology. Jul 2022.
2021
Peterhoff et al. Augmenting the Immune Response against a Stabilized HIV-1 Clade C Envelope Trimer by Silica Nanoparticle Delivery. Vaccines. Jun 2021
Hauser et al. Stepwise Conformational Stabilization of a HIV-1 Clade C Consensus Envelope Trimer Immunogen Impacts the Profile of Vaccine-Induced Antibody Responses. Vaccines. Jul 2021
2020
Lévy Y et al. Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial.PLoS Pathogen. Jun 2020
Hosseinipour MC et al. Phase 1 HIV vaccine trial to evaluate the safety and immunogenicity of HIV subtype C DNA and MF59-adjuvanted subtype C Env protein.Clinical Infectious Diseases. Jan 2020
2019
Giel-Moloney M et al. Recombinant HIV-1 Vaccine Candidates Based on Replication-Defective Flavivirus Vector. Scientific Reports. Dec 2019
Perdiguero B et al. Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses. Frontiers in Immunology. Dec 2019
Rouphael NG et al. DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. The Journal of Clinical Investigation. Nov 2019
Pantaleo G et al. Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. Lancet HIV. Nov 2019
2018
Asbach B et al. Priming with a potent HIV-1 DNA vaccine frames the quality of immune responses prior to a poxvirus and protein boost. Journal of Virology. Nov 2018
Kibler KV et al. Replication-competent NYVAC-KC yields improved immunogenicity to HIV-1 antigens in rhesus macaques, compared to non-replicating NYVAC. Journal of Virology. Nov 2018
Nanvubya A et al. Recruitment and Retention of Participants from Fishing Communities of Lake Victoria in the First Phase I HIV Vaccine Trial in this Community: Experiences of the EV06 Study. HSOA Journal of Vaccines Research & Vaccination. 2018
2017
Amelio P et al. Mixed Th1 and Th2 Mycobacterium tuberculosis-specific CD4 T cell responses in patients with active pulmonary tuberculosis from Tanzania. PLOS Neglected Tropical Diseases. Jul 2017
García-Arriaza J et al. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. Journal of Virology. Apr 2017
2016
Asbach B et al. Streamlining Heterologous DNA-Prime and NYVAC/Protein-Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. Journal of Virology. Mar 2016
Obuku AE et al. Effect of Schistosoma mansoni infection on innate and HIV-1 specific T cell immune responses in HIV-1 infected Ugandan fisher folk. AIDS Research and Human Retroviruses. Jul 2016
2015
García-Arriaza J et al. Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. Journal of Virology, Aug 2015
Shen X et al. Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. Journal of Virology. Aug 2015
2014
Bart PA et al. HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. Journal of Clinical Investigations. Nov 2014
2012
2011
Quakkelaar ED et al. Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS ONE. Feb 2011
Kibler KV et al. Improved NYVAC-based Vaccine Vectors. PLoS One. Nov 2011
2009
2008
Bart P-A et al. EV01: A phase 1 trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine. Jun 2008
Corbett M et al. Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple and immunogenic. Proceedings of the National Academy of Scienses. Feb 2008
Harari A et al. A HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. The Journal of Experimental Medicine. Jan 2008
Gómez CE et al. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Gene Therapy. Apr 2008
McCormack S et al. EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime –NYVAC-C boost to NYVAC-C alone. Vaccine. Jun 2008
Mooij P et al. Differential CD4+ versus CD8+ responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. Journal of Virology. Mar 2008
Vermeulen J et al. TheraVac-02: An open-label phase I study to evaluate the safety of the HIV-1 vaccine MVA-B in chronic HIV-1 infected patients successfully treated with HAART. World AIDS Congress Mexico City, Mexico. 2008 (PDF)
2007
Gómez CE et al. Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. Journal of General Virology. Sep 2007
Gómez CE et al. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1 BX08 gp120 and HIV-1 IIIB Gag-Pol-Nef proteins of clade B. Vaccine. Apr 2007
Gómez CE et al. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine. Dec 2007
2006
Guerra S et al. Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kB-responsive genes in infected HeLa cells. Journal of Virology. Jan 2006
Nájera JL et al. Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of C7L gene. Journal of Virology. Jun 2006